Adelaide, South Australia, Australia
Trajan Nutrition has signed a Memorandum of Understanding with the South Australian Health and Medical Research Institute (SAHMRI) to accelerate the translation in the global market of nutrition testing research led by professors Maria Makrides and Robert Gibson.
Trajan Scientific and Medical established Trajan Nutrition in 2017 as a joint venture with Prof Makrides and Prof Gibson, and recently appointed Mr Marco Baccanti as CEO.
Mr Baccanti, CEO of Trajan Nutrition, comments, “This new agreement will support Trajan Nutrition in offering tailored solutions and technologies for nutrition testing on a global scale; in partnership with research organisations, pathology laboratories, food and supplement companies, health insurance and corporate wellness providers.”
Under the new agreement, Trajan Nutrition and SAHMRI will leverage the know-how and the expertise of the SAHMRI Nutrition Laboratory, an analytical testing and research laboratory entirely dedicated to nutrition tests, perhaps the biggest and best-equipped in the Asia Pacific region.
Professor Steve Wesselingh, Executive Director of SAHMRI, said, “This agreement with Trajan Nutrition is an important example of SAHMRI’s strategy to deliver translation of the results of its medical research activities into therapeutic solutions for patients, and better preventative health approaches.”
Trajan Scientific and Medical enriches the wellbeing of a growing number of communities through improved scientific and medical tools and technologies. They have completed 7 acquisitions over 6 years, increased their workforce to over 450 staff and continue to develop partnerships with unique collaboration models with academia, industry experts and likeminded organisations.
Mr. Stephen Tomisich, CEO of Trajan Scientific and Medical, said, “This marks an important milestone to accelerate our progress with Trajan Nutrition, and more broadly, with the adoption of Trajan’s microsampling technologies, a stronger focus on proactive wellness through patient-centric and delocalized healthcare.”
Photo(L-R): Mr Stephen Tomisich, CEO Trajan Scientific and Medical, Prof Steve Wesselingh, Executive Director SAHMRI, Mr Marco Baccanti, CEO Trajan Nutrition.
Press release [PDF]
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.